Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Inclusion Criteria:

• Have had an established diagnosis of UC for ≥3 months before baseline which includesendoscopic evidence of UC and a histopathology report that supports a diagnosis ofUC.

• Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5to 9 points and endoscopic subscore (ES) of 2 to 3 (confirmed by central review)within 21 days before baseline.

• Participants with a history of UC for greater than or equal to 8 years who have hada surveillance colonoscopy completed within 1 year prior to baseline must havedocumented negative results for colorectal dysplasia and cancer.

• Have obesity, [body mass index (BMI) 30 kilograms per meter squared (kg/m2)]

• Have overweight (BMI ≥27 kg/m2 to <30 kg/m2) and in the presence of at least 1 ofthese weight-related comorbid conditions:

• hypertension

• Type 2 Diabetes Mellitus (T2DM)

• dyslipidemia

• obstructive sleep apnea, or

• cardiovascular disease.

• Have an inadequate response to, loss of response to, or intolerance to at least 1 ofthe conventional medication: oral corticosteroids, oral azathioprine (AZA) or 6-mercaptopurine (6-MP), or oral 5-aminosalicylates (for example, mesalamine,sulfasalazine, olsalazine, and balsalazide) and/or who have an inadequate responseto or a loss of response to, or are intolerant to advanced therapy for UC, definedas: a biologic or biosimilar medication such as anti-tumor necrosis factor (TNF)antibodies; anti-integrin antibodies, Janus kinase (JAK) inhibitors such astofacitinib or upadacitinib, sphingosine 1-phosphate receptor 1inhibitors such asetrasimod or ozanimod, or anti-interleukin(IL)-12p40 antibodies, for example,ustekinumab.

Exclusion Criteria:

• Have a current diagnosis of:

• Crohn's disease

• inflammatory bowel disease (IBD) unclassified (formerly known as indeterminatecolitis), or

• primary sclerosing cholangitis.

• Have had or will need bowel resection or intestinal or intra-abdominal surgery.

• Have evidence of toxic megacolon, or stricture or stenosis within the colon thatcannot be traversed by a sigmoidoscope or colonoscope.

• Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.

• Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6months prior to screening.

• Have a self-reported change in body weight greater than 5% (gain or reduction)within 3 months prior to screening.

• Have a current or recent acute, active infection.